Tags

Type your tag names separated by a space and hit enter

Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
J Med Virol. 2009 Apr; 81(4):722-7.JM

Abstract

Influenza vaccine is considered to reduce influenza-related morbidity and mortality in patients with underlying chronic medical conditions. Because of fear of vaccine shortage during an influenza pandemic, several antigen sparing strategies have been investigated. The immunogenicity of intradermal influenza vaccination with one half the antigenic contents was compared to that of conventional intramuscular vaccination in patients with solid cancer, and adverse events were assessed after vaccination. There was no significant difference between the injection routes in the hemagglutinin inhibition (HI) response and increase in the titer of A/H1N1, A/H3N2, and B 4-6 weeks after the vaccination; seroconversion factors increased by more than 2.5-fold. Seroresponse rates were more than 40% and seroprotection rates were above 70% against all three influenza strains irrespective of the vaccination routes. No serious events were observed, and local skin reactions were more frequent in the intradermal injection recipients than in the intramuscular recipients (32.7% vs. 9.1%). This study shows that intradermal injection of one half the dose of a commercial influenza vaccine elicits immune responses comparable to those elicited by a full dose of intramuscular vaccine among cancer patients, and it can be tolerated without serious adverse reactions.

Authors+Show Affiliations

Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

19235853

Citation

Jo, Yu Mi, et al. "Dose Sparing Strategy With Intradermal Influenza Vaccination in Patients With Solid Cancer." Journal of Medical Virology, vol. 81, no. 4, 2009, pp. 722-7.
Jo YM, Song JY, Hwang IS, et al. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. J Med Virol. 2009;81(4):722-7.
Jo, Y. M., Song, J. Y., Hwang, I. S., Lee, J., Oh, S. C., Kim, J. S., Kim, S. R., Kim, W. J., & Cheong, H. J. (2009). Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. Journal of Medical Virology, 81(4), 722-7. https://doi.org/10.1002/jmv.21186
Jo YM, et al. Dose Sparing Strategy With Intradermal Influenza Vaccination in Patients With Solid Cancer. J Med Virol. 2009;81(4):722-7. PubMed PMID: 19235853.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. AU - Jo,Yu Mi, AU - Song,Joon Young, AU - Hwang,In Sook, AU - Lee,Jacob, AU - Oh,Sang Cheul, AU - Kim,Jun Suk, AU - Kim,Sung Ran, AU - Kim,Woo Joo, AU - Cheong,Hee Jin, PY - 2009/2/25/entrez PY - 2009/2/25/pubmed PY - 2009/3/26/medline SP - 722 EP - 7 JF - Journal of medical virology JO - J. Med. Virol. VL - 81 IS - 4 N2 - Influenza vaccine is considered to reduce influenza-related morbidity and mortality in patients with underlying chronic medical conditions. Because of fear of vaccine shortage during an influenza pandemic, several antigen sparing strategies have been investigated. The immunogenicity of intradermal influenza vaccination with one half the antigenic contents was compared to that of conventional intramuscular vaccination in patients with solid cancer, and adverse events were assessed after vaccination. There was no significant difference between the injection routes in the hemagglutinin inhibition (HI) response and increase in the titer of A/H1N1, A/H3N2, and B 4-6 weeks after the vaccination; seroconversion factors increased by more than 2.5-fold. Seroresponse rates were more than 40% and seroprotection rates were above 70% against all three influenza strains irrespective of the vaccination routes. No serious events were observed, and local skin reactions were more frequent in the intradermal injection recipients than in the intramuscular recipients (32.7% vs. 9.1%). This study shows that intradermal injection of one half the dose of a commercial influenza vaccine elicits immune responses comparable to those elicited by a full dose of intramuscular vaccine among cancer patients, and it can be tolerated without serious adverse reactions. SN - 1096-9071 UR - https://www.unboundmedicine.com/medline/citation/19235853/Dose_sparing_strategy_with_intradermal_influenza_vaccination_in_patients_with_solid_cancer_ L2 - https://doi.org/10.1002/jmv.21186 DB - PRIME DP - Unbound Medicine ER -